Full Text View
Tabular View
No Study Results Posted
Related Studies
Zoledronic Acid to Prevent Bone Loss During Androgen Deprivation Therapy for Prostate Cancer
This study has been completed.
Study NCT00181584   Information provided by Massachusetts General Hospital

First Received on September 9, 2005.   Last Updated on April 27, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Bone Loss
Prostate Cancer
Additional conditions recognized in this trial
Bone Diseases, Metabolic
Prostatic Neoplasms
More general conditions related to this trial
Bone Diseases
Genital Diseases, Male
Genital Neoplasms, Male
Musculoskeletal Diseases
Neoplasms
Neoplasms by Site
Prostatic Diseases
Urogenital Neoplasms
Interventions listed in this trial
Zoledronic acid
Placebo
Additional drug interventions recognized in this trial
Androgens
Diphosphonates
More general drug interventions related to this trial
Bone Density Conservation Agents
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Pharmacologic Actions
Physiological Effects of Drugs
Sponsors listed in this trial
Massachusetts General Hospital
Dana-Farber Cancer Institute


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services